BioCentury | Apr 29, 2015
Company News

Management tracks

...Euronext:TXCL) named Stephane Boissel CEO and promoted Miguel Forte to COO. Boissel was CEO of Genclis S.A.S....
BioCentury | Nov 19, 2012
Company News

DBV, Genclis S.A.S., Hospices Civils de Lyon inflammation, diagnostic news

...in children. The program will be conducted under ImmunAVia, a joint project with diagnostic company Genclis...
...€5 million ($6.4 million) in milestones to develop Viaskin HDM through Phase II testing, while Genclis...
...will retain rights to IP related to its own products. DBV Technologies (Euronext:DBV), Bagneux, France Genclis S.A.S....
BioCentury | Oct 20, 2011
Cover Story

Focusing siRNA on the spleen

Separate academic teams have collaborated with Alnylam Pharmaceuticals Inc. to target small interfering RNAs to immune cells residing in the spleen. The therapeutics silence inflammatory or antigen-presenting immune cells before they migrate to tissues where...
BioCentury | Oct 20, 2011
Distillery Techniques

Technology: Drug delivery

This week in techniques Approach Summary Licensing status Publication and contact information Drug delivery Lipid nanoparticle formulations for spleen-specific delivery of small interfering RNA to macrophages and dendritic cells (DCs) Mouse studies suggest large lipid...
Items per page:
1 - 4 of 4
BioCentury | Apr 29, 2015
Company News

Management tracks

...Euronext:TXCL) named Stephane Boissel CEO and promoted Miguel Forte to COO. Boissel was CEO of Genclis S.A.S....
BioCentury | Nov 19, 2012
Company News

DBV, Genclis S.A.S., Hospices Civils de Lyon inflammation, diagnostic news

...in children. The program will be conducted under ImmunAVia, a joint project with diagnostic company Genclis...
...€5 million ($6.4 million) in milestones to develop Viaskin HDM through Phase II testing, while Genclis...
...will retain rights to IP related to its own products. DBV Technologies (Euronext:DBV), Bagneux, France Genclis S.A.S....
BioCentury | Oct 20, 2011
Cover Story

Focusing siRNA on the spleen

Separate academic teams have collaborated with Alnylam Pharmaceuticals Inc. to target small interfering RNAs to immune cells residing in the spleen. The therapeutics silence inflammatory or antigen-presenting immune cells before they migrate to tissues where...
BioCentury | Oct 20, 2011
Distillery Techniques

Technology: Drug delivery

This week in techniques Approach Summary Licensing status Publication and contact information Drug delivery Lipid nanoparticle formulations for spleen-specific delivery of small interfering RNA to macrophages and dendritic cells (DCs) Mouse studies suggest large lipid...
Items per page:
1 - 4 of 4